Stereotaxis, Inc. Hits New 52-Week Low at USD 1.36

Stereotaxis, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.36 as of July 21, 2026. This significant decline reflects a challenging year for the company, with its stock price plummeting by 58.94% over the past year, contrasting sharply with the S&P 500's performance of 19.09% during the same period. The company's market capitalization stands at USD 177 million, indicating its position within the microcap category. Stereotaxis has not reported a price-to-earnings (P/E) ratio, as it is currently operating at a loss. Additionally, the company has a negative debt-to-equity ratio of -0.68 and a return on equity of -106.31%, highlighting financial difficulties. The price-to-book ratio is recorded at 9.45, suggesting that the stock may be trading at a premium relative to its book value. As Stereotaxis navigates these financial metrics, the recent drop to its 52-week low underscores the ongoing volatility in its stock performance.